SCHEMBL4597495

SCHEMBL4597495

NC(C(=O)N1CCCCC1)c1ccc(Oc2ccc(C(=O)NO)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.44
ALOX15 P16050 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ADAM17 P78536 3/20 0.44
MMP1 P03956 2/20 0.44
MMP3 P08254 2/20 0.44
MMP13 P45452 2/20 0.44
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX5 P09917 1/20 0.42
HDAC8 Q9BY41 5/20 0.42
HDAC1 Q13547 4/20 0.42
GFER P55789 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124921 0.81 HDAC1 (0.48) HDAC6HDAC8HDAC1OPRM1OPRK1
SCHEMBL7038451 0.78 MMP1 (0.55) ALOX15HTTSMN1; SMN2ADAM17MMP1
SCHEMBL7038457 0.78 MMP1 (0.55) ALOX15HTTSMN1; SMN2ADAM17MMP1
SCHEMBL4596780 0.73 HDAC8 (0.51) HDAC6HDAC8HDAC1
SCHEMBL13632802 0.73 HPGD (0.53) HTTSMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL4984200 0.73 HPGD (0.53) HTTSMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL21628436 0.71 HDAC6 (0.59) HDAC6ALOX15HTTSMN1; SMN2ADAM17
Hydrochloric Acid SCHEMBL6261119 0.71 GAA (0.51) HTTALDH1A1HPGDKMT2AMEN1
SCHEMBL5007669 0.71 DPP4 (0.54) HPGDKMT2AHRH2HRH1TSHR
SCHEMBL14027830 0.71 DPP4 (0.54) HPGDKMT2AHRH2HRH1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives BEXEL PHARMACEUTICALS. INC. 2008-08-21 US claimed
EP-1906731-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES Bexel Pharmaceuticals Inc (US) 2008-04-09 EP claimed
WO-2007005603-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES BEXEL PHARMACEUTICALS, INC. (US) 2007-01-11 WO claimed
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives HGFAC, HCAR2, BCAT1 HDAC6 639/4885ALOX15 250/4885HTT 1203/4885
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives HGFAC, HCAR2, BCAT1 HDAC6 684/4885ALOX15 295/4885HTT 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.